At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 100 enrolled
Drug / intervention
Multiple dose of EO2401biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Open-Label, First-in-Human, Phase 1b/2a Trial of EO2401, a Novel Multipeptide Therapeutic Vaccine, With and Without Check Point Inhibitor, Following Standard Treatment in Patients With Progressive Glioblastoma
In Brief
A Phase 2 clinical trial evaluating Multiple dose of EO2401 for Glioblastoma, Adult. Completed, enrolled 100 participants across 10 sites in 4 countries.
Detailed Summary
The purpose of this study is to assess the safety, tolerability, immunogenicity, and preliminary efficacy of EO2401 in patients with unequivocal evidence of progressive or first recurrent glioblastoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlioblastoma, Adult
CountriesFrance, Germany, Spain, United States
CollaboratorsCovance
Timeline
Phase 2CompletedFinished
2020202120222023202420252026
First PostedOct 2019
Enrollment StartJul 2020
Primary CompletionMar 2024
TodayJul 2026
First PostedOct 4, 2019
Enrollment StartJul 13, 2020
Primary CompletionMar 4, 2024
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 6.7 years ago
Interventions
Multiple dose of EO2401biological
Multiple dose administration of EO2401 coadministered with or without nivolumab (and bevacizumab, US only) during the priming phase